Re. Brenner et al., Effects of dexamethasone on proliferation, chemotaxis, collagen I, and fibronectin-metabolism of human fetal lung fibroblasts, PEDIAT PULM, 32(1), 2001, pp. 1-7
Premature infants at risk for bronchopulmonary dysplasia (BPD) are often tr
eated with dexamethasone (Dex), which has been shown to suppress inflammato
ry processes in the lung. To elucidate a possible direct influence on the f
ibroproliferative component of the disease, we studied the effects of Dex i
n therapeutic and supratherapeutic dosages (5-50 nmol/L) on proliferation,
chemotaxis, procollagen I, and fibronectin metabolism of human fetal lung f
ibroblasts in vitro.
Proliferation was inhibited by Dex in a dose-dependent manner. Chemotactic
activity in response to conditioned medium of human fetal fibroblasts also
showed a dose-dependent inhibition after pretreatment with Dex. The amount
of procollagen I C-terminal propeptide and fibronectin per cell in the cell
culture supernatant was increased in the presence of Dex.
Our results show that Dex does not uniformly suppress the fibroproliferativ
e activity of human fetal lung fibroblasts, which may explain in pari the u
nsatisfactory long-term effects of Dex treatment in BPD. (C) 2001 Wiley-Lis
s, Inc.